New biologic therapeutics for ulcerative colitis and Crohn's disease

Expert Opinion on Biological Therapy

Volumn 14, Issue 5, 2014, Pages 583-600

  Mozaffari, Shilan ^a   Nikfar, Shekoufeh ^a,b   Abdolghaffari, Amir Hossein ^c,d   Abdollahi, Mohammad ^a,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adalimumab; Anti TNF drugs; Certolizumab; Crohn's disease; Golimumab; Infliximab; Natalizumab; Remission; Systematic review; Ulcerative colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA4 INTEGRIN; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; NATALIZUMAB; ONERCEPT; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB; BIOLOGICAL PRODUCT;

BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HOSPITAL SERVICE; HUMAN; IMMUNOMODULATION; INCIDENCE; INFLAMMATORY BOWEL DISEASE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; THERAPY EFFECT; ULCERATIVE COLITIS; COLITIS, ULCERATIVE;

BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS;

EID: 84896464636     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.885945     Document Type: Review

References (93)

1. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:597-605
2. Walsh A, Mabee J, Trivedi K. Inflammatory bowel disease. Prim Care 2011;38:415-32
3. Xavier RJ, Podilsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34
4. Nikfar S, Rahimi R, Rezaie A, et al. A meta-Analysis of the efficacy of sulfasalazine in comparison with 5-Aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54:1157-70
5. Rahimi R, Nikfar S, Rezaie A, et al. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: A meta-Analysis. Dig Dis Sci 2009;54:712-21
6. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: Systematic review and meta-Analysis. Am J Gastroenterol 2011;106:590-9
7. Rahimi R, Nikfar S, Abdollahi M. Do anti-Tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-Analysis of controlled clinical trials. Biomed Pharmacother 2007;61:75-80
8. Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: A systematic review and meta-Analysis of placebocontrolled trials. Curr Pharm Des 2010;16:3684-98
9. Ehteshami-Afshar S, Nikfar S, Rezaie A, et al. A systematic review and metaanalysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 2011;7:1000-12
10. Abdolghaffari AH, Nikfar S, Rahimi HR, et al. A comprehensive review of antibiotics in clinical trials for inflammatory bowel disease. Int J Pharmacol 2012;8:596-613
11. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: A systematic review and meta-Analysis. Arch Med Sci 2010;6:49-55
12. Rezaie A, Eshghtork A, Zamani M, et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factorbeta1 in relation to disease activity in Crohn's disease patients. Ann NY Acad Sci 2006;1091:110-22
13. Rahimi R, Nikfar S, Rezaie A, et al. A meta-Analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008;4:185-90
14. Müllner K, Miheller P, Hersze'nyi L, Tulassay Z. Probiotics in the Management of Crohn's Disease and Ulcerative Colitis. Curr Pharm Des 2013. [Epub ahead of print]
15. Salari P, Abdollahi M. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012;21:261-4
16. Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: Do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008;7:129-35
17. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: Role of ATP. Recent Patents Endocr Metabol Immune Drug Discov 2009;3:69-75
18. Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: A comprehensive review of evidences. Curr Pharm Des 2011;17:4372-8
19. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig Dis Sci 2009;54:471-80
20. Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010;16:4504-14
21. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24
22. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause? Dig Dis Sci 2007;52:2015-21
23. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: Role of ATP. Recent Patents Endocr Metab Immune Drug Discov 2009;3:69-75
24. Dahan S, Roth-Walter F, Arnaboldi P, et al. Epithelia: Lymphocyte interactions in the gut. Immunol Rev 2007;215:243-53
25. Rezaie A, Taghavi Bayat B, Abdollahi M. Biologic Management of Fistulizing Crohn's Disease. Int J Pharmacol 2005;1:17-24
26. Neurath MF. IL-23: A master regulator in Crohn's disease. Nat Med 2007;13:26-8
27. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/ 23 monoclonal antibody, in patients with moderate-To-severe Crohn's disease. Gastroenterology 2008;135:1130-41
28. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17
29. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91
30. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population based study. Gastroenterology 2001;123:255-60
31. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-Alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-Alpha and activates immune effector functions. Cytokine 1995;7:251-9
32. Miheller P, Lakatos PL, Horva'th G, et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe-A Hungarian nationwide observational study. BMC Gastroenterol 2009;9:66
33. Ardizzone S, Colombo E, Maconi G, et al. Infliximab in treatment of Crohn's disease: The Milan experience. Dig Liver Dis 2002;34:411-18
34. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
35. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012;143:62-9
36. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
37. Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010;13:472-81
38. Keshav S, Vana'sek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-Administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One 2013;8:e60094
39. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520-6
40. Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-To-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204-13
41. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-Tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33
42. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007;56:1232-9
43. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patientreported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41
44. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011;60:780-7
45. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2012;142:257-65
46. Nikfar S, Ehteshami-Afshar S, Abdollahi M. Is certolizumab pegol safe and effective in the treatment of patients with moderate to severe Crohn's disease? A meta-Analysis of controlled clinical trials. Iran Red Crescent Med J 2013;15:668-75
47. Hanauer SB, Panes J, Colombel JF, et al. Clinical trial: Impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-93
48. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn's disease: A placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9:670-8
49. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
50. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
51. Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: Results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8:696-702
52. Lichtenstein GR, Thomsen OØ, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9
53. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-95
54. Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF-Alpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96
55. Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate-To-severe Crohn's disease: A randomized, doubleblind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:888-93
56. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebocontrolled trial. Gastroenterology 2001;121:1088-94
57. Feagan B, Sandborn W, Marano C, et al. A phase 2/3 randomized, placebocontrolled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. CDDW/Annual CASL; 1-4 March 2013; Victoria, British Columbia
58. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25
59. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 2007;132:1672-83
60. Feagan BG, Sandborn WJ, Hass S, et al. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 2007;102:2737-46
61. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7integrin. N Engl J Med 2005;352:2499-507
62. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7
63. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9
64. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
65. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21
66. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012;143:62-9
67. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: An analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82
68. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13:2-11
69. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74
70. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46
71. Yacyshyn BR, Chey WY, Goff J, et al. Double-blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, c (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6
72. Van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double-bind, escalating dose study of alicaforsen enema in ulcerative colitis. Gut 2004;53:1646-51
73. Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009;104:1976-83
74. Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96
75. Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: Improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50
76. Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: The effects of certolizumab pegol therapy on work productivity in patients with moderate-To-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85
77. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: A randomized trial. Ann Intern Med 2007;146:829-38
78. Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-To-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204-13
79. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-To-severe Crohn's disease: An exploratory study. Aliment Pharmacol Ther 2004;20:1337-46
80. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18
81. Schreiber S, Lawrance IC, Thomsen OØ, et al. Randomised clinical trial: Certolizumab pegol for fistulas in Crohn's disease-subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011;33:185-93
82. Feagan BG, Hanauer SB, Coteur G, Schreiber S. Evaluation of a daily practice composite score for the assessment of Crohn's disease: The treatment impact of certolizumab pegol. Aliment Pharmacol Ther 2011;33:1143-51
83. Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8
84. A safety and effectiveness study of golimumab in Japanese patients with Moderately to Severely Active Ulcerative Colitis. Janssen Pharmaceutical K.K. 2013. Available from: Http://clinicaltrial. gov/ct2/show/NCT01863771? term=NCT01863771&rank=1
85. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2014;146:85-95
86. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2014;146:96-109
87. An Efficacy and Safety Study of Golimumab in Participants with Ulcerative Colitis. Janssen Research & Development, LLC. 2007. Available from: Http://clinicaltrial. gov/ct2/show/NCT00488774? term=NCT00488774&rank=1
88. Safety and Efficacy of Natalizumab in Combination with Remicade in the Treatment of Crohn's Disease. Elan Pharmaceuticals. 2003. Available from: Http://clinicaltrial. gov/ct2/show/NCT00055536? term=NCT00055536&rank=1
89. Safety, Tolerability and Effectiveness of Natalizumab in Adolescents with Active Crohn's Disease. Elan Pharmaceuticals. 2003. Available from: Http://clinicaltrial. gov/ct2/show/NCT00055367? term=NCT00055367&rank=1
90. A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease. Elan Pharmaceuticals. 2004. Available from: Http://clinicaltrial. gov/ct2/show/NCT00078611? term=NCT00078611&rank=1
91. Study of Vedolizumab in Patients with Moderate to Severe Crohn's Disease (GEMINI III). Millennium Pharmaceuticals, Inc. 2010. Available from: Http://clinicaltrial. gov/ct2/show/NCT01224171? term=NCT01224171&rank=1
92. An Open-label Study of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease (GEMINI LTS). Millennium Pharmaceuticals, Inc. 2008. Available from: Http://clinicaltrial. gov/ct2/show/NCT00790933? term=NCT00790933&rank=1
93. Esmaily H, Vaziri-Bami A, Miroliaee AE, et al. The correlation between NF-kappaB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011;25:723-33